ABIN6970859 (T 3 ) and ABIN6970688 (T 4 ))
Kicking off 2026: Sparked by the long-awaited rise of non-opioid treatments, the first-ever - will capitalize on Vertex's recent success to transform efficacy and tolerability of pain management with Nav 1.8 & beyond: With rising anticipation for new targets like tau and LRRK2, the & returns as your flagship end-to-end forum for building on anti-amyloid approvals and strengthening biomarker assessments to reinvigorate the neurodegenerative treatment landscape: Concentrating on earlier-stage innovation, will unite those dedicated to translating discoveries of glial biology and peripheral immune pathways into novel approaches to target neuroinflammation across the neurodegenerative disease spectrum: Full details of the 2026 event schedule can be found in your copy of the World CNS 2026 Prospectus below
[DOI] [PubMed] [Google Scholar] 104.D Archivio M., Filesi C., Di Benedetto R., Gargiulo R., Giovannini C., Masella R
Exercise ameliorates diabetic kidney disease in type 2 diabetic fatty rats
doi: 10.1021/cr200084z 37 YoshidaYUmenoAShichiriM
Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo
